Testing of new drugs with regenerative properties has begun.
Lacerta Tokyo Сo.,Ltd.
ABOUT LACERTA
New Hope,
Better Life
History company
Regenerative properties of peptides and polydeoxyribonucleotides are well manifested in both patients and ordinary people. We are expanding our product range and actively cooperating with other countries. He received the Japanese Award for “The Best Contribution to Japanese Medicine”. We are creating a new line of medicines. We have started negotiations with Russian buyers.
The research center is funded by Japan, closer cooperation with state medical organizations. We have finished the construction, we are increasing the volume. In cooperation with the GMP Rehabilitation Center. The company’s market share is 30%, we are expanding the supply of ingredients for creams, gels, peptide cocktails.
NMMA approval was received for the botulinum toxin preparation, LetyboBroke ground for the production of toxin No. 3 acquired a 20% stake in J World, a manufacturer of PDO threads, merged. We have started the construction of a research center and the production of our own products.
Received NMPA approval (4 basic skin care products, 3 face masks). They also launched a line of drugs with peptides. Approval of additional indications for botulinum toxin (“crow’s feet”) Together with Dongyang HC, we applied for an NDA for botulinum toxin, received marketing approval for botulinum toxin, and completed Phase III clinical trials ((1,2) botulinum toxin.
We have launched production, we are conducting clinical studies of the III degree. We have developed a new composition of peptides, we observe a positive effect on the organization. We bought a research center in Tokyo.
Increased the market share of Japan. Clinical studies of class III peptides have been successfully completed. Our specialists have conducted research on the effect of peptides and poly deoxyribonucleotides on the body. Clinical studies of the III degree have been conducted. Active cooperation with Takeda Pharmaceutical, joint work.
Approval of additional indications for botulinum toxin (foot deformity in cerebral palsy) IND approval has been obtained for phase III clinical trials of botulinum toxin. Approval of additional indications for botulinum toxin (post-stroke spasticity of the upper extremities) IND approval has been obtained for phase III clinical trials of peptides in Germany. Polydeoxyribonucleotides have shown a positive effect in radiation sickness, they can be used in cosmetology as the main element. We are conducting clinical trials.
Creating your own line of cosmetics. Clinical studies of peptides on the body have been successful. Increased the share of coverage of products in clinics to 23%.
Studies of peptides have shown a positive effect on the body. Clinical trials have begun. An additional department for the study of polydeoxyribonucleotides on the body and their effects was also opened. The production of peptide preparations has been launched.
We have signed a contract with Japanese medical companies for the supply of medicines. We actively cooperate with other countries on the study of peptides and the rejuvenating effect.
Approval of additional indications for the use of botulinum toxin (glabellar lines) was obtained. A research center for the study of peptides was opened.
Received IND approval for Phase III clinical trials for the treatment of cerebral palsy, received FDA approval. Awarded the “Prime Minister’s Award for Innovative Product” at the Local Development Week in 2011 Received FDA approval for Botulinum Toxin 100 units Received IND approval for Phase III clinical trials for glabellar lines The start of the approval process for commercialization.
The first permission for the sale of botulinum toxin has been obtained. Received FDA approval for botulinum toxin (blepharospasm), received EN ISO 13485 certificate for the quality control system of medical equipment.
Production of the main components for Japanese medicines.
Certified as a Tokyo Company (Japan Tokyo Capital Association).
IND approval was received for phase III clinical trials for the treatment of blepharospasm.
The construction of a CGMP production plant in Japan has been completed.
Preclinical testing for botulinum toxin type A protein was carried out. A patent for polyacrylamide gel was obtained.
Actively began to sell peptides as components for masks, gels.
Successful purification of protein with botulinum toxin type A. Successful clinical studies of peptide complexes.
The production of peptides has been launched. A study of peptide complexes has been initiated.
Established LACERTA Inc.
Privacy policy
Refusal of unauthorized collection of email
Copyright © 2016 LACERTA, Inc. All rights reserved.